Today, Pfizer announced that it has launched or is launching the following three biosimilars in the United States at the following prices:
- ZIRABEV (bevacizumab-bvzr), which was introduced to the U.S. market on December 31, 2019, at a Wholesale Acquisition Cost (WAC) of $61.34 per 10 mg, which represents a 23% discount off the WAC of the AVASTIN reference product;
- RUXIENCE (rituximab-pvvr), which was introduced to the U.S. market today, January 23, 2020, at a WAC of $71.68 per 10 mg, which represents a 24% discount off the WAC of the RITUXAN reference product; and
- TRAZIMERA (trastuzumab-qyyp), which will be made available on February 15, 2020, at a WAC of $80.74 per 10 mg, which represents a 22% discount off the WAC of the HERCEPTIN reference product.
The U.S. FDA approved each of these biosimilar products in 2019. According to Pfizer, each biosimilar product is expected to launch at the lowest WAC among bevacizumab, rituximab or trastuzumab products currently on the market.
The launch dates announced today are consistent with guidance that Pfizer provided to investors this past fall.
